Biobank Leukemia, Myeloma, Lymfoma and Myelofibrosis
Completed
- Conditions
- Leukemia10018849
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 1950
Inclusion Criteria
Patients 18 or older, able to state his/her wishes and has (or is suspected to have) a hematological disease.
Exclusion Criteria
If diagnosis demonstrates that the patient does not have any of the hematological diseases, as mentioned under the inclusion citeria, he/she is excluded.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>This project intends to gain knowledge on the properties (such as DNA features)<br /><br>of the stored tissue or cells. These data are combined with clinical data of<br /><br>the disease, sensitivity to treatment and possibly with important environmental<br /><br>factors and patient data (i.e. age, previous diseases).<br /><br>From these analyses knowledge can be gained about:<br /><br>- the nature and possibly the origin of the disease<br /><br>- reasons why the disease responds well or poorly to the applied treatment<br /><br>- the treatment outcome. </p><br>
- Secondary Outcome Measures
Name Time Method <p>A 'minimal dataset' describing the collected clinical data/variables, has been<br /><br>drafted for every hematological disease in agreement with all eight UMC's (see<br /><br>attachment 1 'Minimal dataset' of the 'Reglement Parel Leukemie, Myeloom,<br /><br>Lymfoom en Myelofibrosis, which is added to the Protocol Biobank 'Leukemie,<br /><br>Myeloom, Lymfklierkanker').</p><br>